Company Encyclopedia
View More
name
SynBio
CP00070.US
News
View More

Cathie Wood Doubles Down on Self-Driving and Gene-Editing Stocks Ahead of 2026

Cathie Wood's ARK Invest has increased its holdings in WeRide Inc. and CRISPR Therapeutics, signaling confidence in self-driving and gene-editing sectors. The firm purchased shares worth approximately $902,000 in WeRide and $585,000 in CRISPR. Meanwhile, ARK reduced its stake in Ibotta Inc., reflecting a strategic portfolio rebalancing. These moves indicate ARK's continued interest in innovative technologies ahead of 2026.

GuruFocus·
US
CRSP
-2.87%
GuruFocus·
US
CRSP
-2.87%

Cathie Wood Bets Big On Self-Driving and Gene-Editing Stocks Ahead of 2026

Cathie Wood's ARK Invest is increasing its holdings in WeRide Inc. and CRISPR Therapeutics, signaling confidence in self-driving and gene-editing sectors. Recent purchases through ARK ETFs total approximately $1.487 million. ARK also reduced its stake in Ibotta Inc., reflecting a strategic portfolio rebalancing.

GuruFocus·
US
CRSP
-2.87%
GuruFocus·
US
CRSP
-2.87%

Ginkgo Bioworks Holdings Insider Sellers Miss The Bus As Stock Jumps 10.0%

Ginkgo Bioworks Holdings' stock rose 10% last week, but insiders who sold shares at an average price of $10.99 are likely better off, as the current price is $8.91. The largest insider sale was by Independent Director Christian O. Henry, who sold $220k worth of shares. Insiders own 17% of the company, aligning their interests with shareholders. No insider trades occurred last quarter, and there are warning signs for the company. Investors should consider other opportunities.

Simplywall·
US
DNA
-5.72%
Simplywall·
US
DNA
-5.72%

Cathie Wood Adds to WeRide (WRD) and CRISPR, Trims Ibotta (IBTA) in Holiday Trades, 12/24/25

Cathie Wood's ARK Invest made trades on December 24, adding to positions in WeRide (WRD) and CRISPR Therapeutics (CRSP), while trimming its stake in Ibotta (IBTA). ARK bought 101,637 shares of WeRide and 10,353 shares of CRISPR, showing confidence in these companies. Wall Street analysts rate WeRide as a "Strong Buy" with a 67% upside, CRISPR as a "Moderate Buy," and Ibotta as "Hold."

Tip Ranks·
US
CRSP
-2.87%
US
WRD
-1.36%
Tip Ranks·
US
CRSP
-2.87%
US
WRD
-1.36%

Beam Therapeutics (BEAM) Receives a Buy from Evercore ISI

Evercore ISI's Cory Kasimov maintains a Buy rating on Beam Therapeutics with a $35 price target. Shares closed at $27.77. Analysts suggest a Strong Buy consensus with a $43 average price target, indicating a 54.84% upside. Bank of America Securities also maintains a Buy rating with a $43 target.

Tip Ranks·
US
BEAM
-0.57%
Tip Ranks·
US
BEAM
-0.57%
Posts
View More

$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...

© 2025 Longbridge｜Disclaimer